INT J CANCER 润色咨询

INTERNATIONAL JOURNAL OF CANCER

出版年份：暂无数据 年文章数：9003 投稿命中率： 开通期刊会员，数据随心看

出版周期：Semimonthly 自引率：2.5% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=1079807, encodeId=415e10e98073a, content=想问下各位大佬，为什么我收不到密码重置的邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:16:22 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3<br>偏重的研究方向：Meta;epidemiology;Cancer<br>经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077723, encodeId=879010e772339, content=挺好的，审稿接收快。之前中过一篇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/15/f7f2b6fa740df678d917e5f3794e5f11.jpg, createdBy=3b832056782, createdName=lambofgod, createdTime=Tue Dec 07 12:57:30 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954201, encodeId=cb2f954201de, content=Under Evaluation已然2周了，催稿没有回复请问这个状态是否正常？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLlINtMomu7O8KxsBW5vjfZau6S8ibwBPphK72hkHBb60gAlxB81LJib2lmRibVUmoBkg0Zry8ZWGPicA/132, createdBy=421e2171722, createdName=走散的晴天, createdTime=Tue Apr 06 13:57:17 CST 2021, time=2021-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120726, encodeId=18a62120e268e, content=请问一般under evaluation几天呀，已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90f98527616, createdName=ms3000001615675881, createdTime=Tue Mar 21 10:52:33 CST 2023, time=2023-03-21, status=1, ipAttribution=弗吉尼亚), GetPortalCommentsPageByObjectIdResponse(id=2115287, encodeId=3d99211528e03, content=偏重的研究方向：Cancer<br>经验分享：请问这个杂志接收生信和试验结合的临床文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70e15211770, createdName=1475fbf4m67暂无昵称, createdTime=Sat Feb 18 18:24:57 CST 2023, time=2023-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1238658, encodeId=36641238658e8, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享：Under evaluation<br><br>IJC-22-1946<br>好几天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小郝, createdTime=Sun Aug 14 17:48:05 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193008, encodeId=1bad11930087c, content=请问这个杂志要求提供原始数据吗？细胞STR鉴定是必须的吗？如果是那什么时候会要呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3b5453190, createdName=ms5000001945010335, createdTime=Sun Feb 13 17:05:02 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880588, encodeId=4269880588d1, content=请问这个杂志收综述嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201025/8eb3ba664d3e470b851a46cc65b07783/2838e99db9824e3ab062239a32b94ea0.jpg, createdBy=e8705227503, createdName=14792e5am71(暂无昵称), createdTime=Sat Aug 29 13:51:28 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079809, encodeId=980410e980994, content=想问下各位大佬，为什么我收不到密码重置的邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:27:38 CST 2021, time=2021-12-14, status=1, ipAttribution=)]
    2021-12-14 ms9482609815413700

    想问下各位大佬，为什么我收不到密码重置的邮件呢？

    2

    展开2条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=1079807, encodeId=415e10e98073a, content=想问下各位大佬，为什么我收不到密码重置的邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:16:22 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3<br>偏重的研究方向：Meta;epidemiology;Cancer<br>经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077723, encodeId=879010e772339, content=挺好的，审稿接收快。之前中过一篇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/15/f7f2b6fa740df678d917e5f3794e5f11.jpg, createdBy=3b832056782, createdName=lambofgod, createdTime=Tue Dec 07 12:57:30 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954201, encodeId=cb2f954201de, content=Under Evaluation已然2周了，催稿没有回复请问这个状态是否正常？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLlINtMomu7O8KxsBW5vjfZau6S8ibwBPphK72hkHBb60gAlxB81LJib2lmRibVUmoBkg0Zry8ZWGPicA/132, createdBy=421e2171722, createdName=走散的晴天, createdTime=Tue Apr 06 13:57:17 CST 2021, time=2021-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120726, encodeId=18a62120e268e, content=请问一般under evaluation几天呀，已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90f98527616, createdName=ms3000001615675881, createdTime=Tue Mar 21 10:52:33 CST 2023, time=2023-03-21, status=1, ipAttribution=弗吉尼亚), GetPortalCommentsPageByObjectIdResponse(id=2115287, encodeId=3d99211528e03, content=偏重的研究方向：Cancer<br>经验分享：请问这个杂志接收生信和试验结合的临床文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70e15211770, createdName=1475fbf4m67暂无昵称, createdTime=Sat Feb 18 18:24:57 CST 2023, time=2023-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1238658, encodeId=36641238658e8, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享：Under evaluation<br><br>IJC-22-1946<br>好几天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小郝, createdTime=Sun Aug 14 17:48:05 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193008, encodeId=1bad11930087c, content=请问这个杂志要求提供原始数据吗？细胞STR鉴定是必须的吗？如果是那什么时候会要呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3b5453190, createdName=ms5000001945010335, createdTime=Sun Feb 13 17:05:02 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880588, encodeId=4269880588d1, content=请问这个杂志收综述嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201025/8eb3ba664d3e470b851a46cc65b07783/2838e99db9824e3ab062239a32b94ea0.jpg, createdBy=e8705227503, createdName=14792e5am71(暂无昵称), createdTime=Sat Aug 29 13:51:28 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079809, encodeId=980410e980994, content=想问下各位大佬，为什么我收不到密码重置的邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:27:38 CST 2021, time=2021-12-14, status=1, ipAttribution=)]
    2022-03-04 1221c8e5m44(暂无昵称)

    审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3
    偏重的研究方向：Meta;epidemiology;Cancer
    经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。

    2

    展开2条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=1079807, encodeId=415e10e98073a, content=想问下各位大佬，为什么我收不到密码重置的邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:16:22 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3<br>偏重的研究方向：Meta;epidemiology;Cancer<br>经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077723, encodeId=879010e772339, content=挺好的，审稿接收快。之前中过一篇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/15/f7f2b6fa740df678d917e5f3794e5f11.jpg, createdBy=3b832056782, createdName=lambofgod, createdTime=Tue Dec 07 12:57:30 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954201, encodeId=cb2f954201de, content=Under Evaluation已然2周了，催稿没有回复请问这个状态是否正常？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLlINtMomu7O8KxsBW5vjfZau6S8ibwBPphK72hkHBb60gAlxB81LJib2lmRibVUmoBkg0Zry8ZWGPicA/132, createdBy=421e2171722, createdName=走散的晴天, createdTime=Tue Apr 06 13:57:17 CST 2021, time=2021-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120726, encodeId=18a62120e268e, content=请问一般under evaluation几天呀，已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90f98527616, createdName=ms3000001615675881, createdTime=Tue Mar 21 10:52:33 CST 2023, time=2023-03-21, status=1, ipAttribution=弗吉尼亚), GetPortalCommentsPageByObjectIdResponse(id=2115287, encodeId=3d99211528e03, content=偏重的研究方向：Cancer<br>经验分享：请问这个杂志接收生信和试验结合的临床文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70e15211770, createdName=1475fbf4m67暂无昵称, createdTime=Sat Feb 18 18:24:57 CST 2023, time=2023-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1238658, encodeId=36641238658e8, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享：Under evaluation<br><br>IJC-22-1946<br>好几天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小郝, createdTime=Sun Aug 14 17:48:05 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193008, encodeId=1bad11930087c, content=请问这个杂志要求提供原始数据吗？细胞STR鉴定是必须的吗？如果是那什么时候会要呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3b5453190, createdName=ms5000001945010335, createdTime=Sun Feb 13 17:05:02 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880588, encodeId=4269880588d1, content=请问这个杂志收综述嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201025/8eb3ba664d3e470b851a46cc65b07783/2838e99db9824e3ab062239a32b94ea0.jpg, createdBy=e8705227503, createdName=14792e5am71(暂无昵称), createdTime=Sat Aug 29 13:51:28 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079809, encodeId=980410e980994, content=想问下各位大佬，为什么我收不到密码重置的邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:27:38 CST 2021, time=2021-12-14, status=1, ipAttribution=)]
    2021-12-07 lambofgod

    挺好的，审稿接收快。之前中过一篇

    2

    展开2条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=1079807, encodeId=415e10e98073a, content=想问下各位大佬，为什么我收不到密码重置的邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:16:22 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3<br>偏重的研究方向：Meta;epidemiology;Cancer<br>经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077723, encodeId=879010e772339, content=挺好的，审稿接收快。之前中过一篇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/15/f7f2b6fa740df678d917e5f3794e5f11.jpg, createdBy=3b832056782, createdName=lambofgod, createdTime=Tue Dec 07 12:57:30 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954201, encodeId=cb2f954201de, content=Under Evaluation已然2周了，催稿没有回复请问这个状态是否正常？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLlINtMomu7O8KxsBW5vjfZau6S8ibwBPphK72hkHBb60gAlxB81LJib2lmRibVUmoBkg0Zry8ZWGPicA/132, createdBy=421e2171722, createdName=走散的晴天, createdTime=Tue Apr 06 13:57:17 CST 2021, time=2021-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120726, encodeId=18a62120e268e, content=请问一般under evaluation几天呀，已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90f98527616, createdName=ms3000001615675881, createdTime=Tue Mar 21 10:52:33 CST 2023, time=2023-03-21, status=1, ipAttribution=弗吉尼亚), GetPortalCommentsPageByObjectIdResponse(id=2115287, encodeId=3d99211528e03, content=偏重的研究方向：Cancer<br>经验分享：请问这个杂志接收生信和试验结合的临床文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70e15211770, createdName=1475fbf4m67暂无昵称, createdTime=Sat Feb 18 18:24:57 CST 2023, time=2023-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1238658, encodeId=36641238658e8, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享：Under evaluation<br><br>IJC-22-1946<br>好几天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小郝, createdTime=Sun Aug 14 17:48:05 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193008, encodeId=1bad11930087c, content=请问这个杂志要求提供原始数据吗？细胞STR鉴定是必须的吗？如果是那什么时候会要呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3b5453190, createdName=ms5000001945010335, createdTime=Sun Feb 13 17:05:02 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880588, encodeId=4269880588d1, content=请问这个杂志收综述嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201025/8eb3ba664d3e470b851a46cc65b07783/2838e99db9824e3ab062239a32b94ea0.jpg, createdBy=e8705227503, createdName=14792e5am71(暂无昵称), createdTime=Sat Aug 29 13:51:28 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079809, encodeId=980410e980994, content=想问下各位大佬，为什么我收不到密码重置的邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:27:38 CST 2021, time=2021-12-14, status=1, ipAttribution=)]
    2021-04-06 走散的晴天

    Under Evaluation已然2周了，催稿没有回复请问这个状态是否正常？

    2

    展开2条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=1079807, encodeId=415e10e98073a, content=想问下各位大佬，为什么我收不到密码重置的邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:16:22 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3<br>偏重的研究方向：Meta;epidemiology;Cancer<br>经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077723, encodeId=879010e772339, content=挺好的，审稿接收快。之前中过一篇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/15/f7f2b6fa740df678d917e5f3794e5f11.jpg, createdBy=3b832056782, createdName=lambofgod, createdTime=Tue Dec 07 12:57:30 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954201, encodeId=cb2f954201de, content=Under Evaluation已然2周了，催稿没有回复请问这个状态是否正常？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLlINtMomu7O8KxsBW5vjfZau6S8ibwBPphK72hkHBb60gAlxB81LJib2lmRibVUmoBkg0Zry8ZWGPicA/132, createdBy=421e2171722, createdName=走散的晴天, createdTime=Tue Apr 06 13:57:17 CST 2021, time=2021-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120726, encodeId=18a62120e268e, content=请问一般under evaluation几天呀，已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90f98527616, createdName=ms3000001615675881, createdTime=Tue Mar 21 10:52:33 CST 2023, time=2023-03-21, status=1, ipAttribution=弗吉尼亚), GetPortalCommentsPageByObjectIdResponse(id=2115287, encodeId=3d99211528e03, content=偏重的研究方向：Cancer<br>经验分享：请问这个杂志接收生信和试验结合的临床文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70e15211770, createdName=1475fbf4m67暂无昵称, createdTime=Sat Feb 18 18:24:57 CST 2023, time=2023-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1238658, encodeId=36641238658e8, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享：Under evaluation<br><br>IJC-22-1946<br>好几天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小郝, createdTime=Sun Aug 14 17:48:05 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193008, encodeId=1bad11930087c, content=请问这个杂志要求提供原始数据吗？细胞STR鉴定是必须的吗？如果是那什么时候会要呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3b5453190, createdName=ms5000001945010335, createdTime=Sun Feb 13 17:05:02 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880588, encodeId=4269880588d1, content=请问这个杂志收综述嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201025/8eb3ba664d3e470b851a46cc65b07783/2838e99db9824e3ab062239a32b94ea0.jpg, createdBy=e8705227503, createdName=14792e5am71(暂无昵称), createdTime=Sat Aug 29 13:51:28 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079809, encodeId=980410e980994, content=想问下各位大佬，为什么我收不到密码重置的邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:27:38 CST 2021, time=2021-12-14, status=1, ipAttribution=)]
    2023-03-21 ms3000001615675881 来自弗吉尼亚

    请问一般under evaluation几天呀，已经10天了

    1

    展开1条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=1079807, encodeId=415e10e98073a, content=想问下各位大佬，为什么我收不到密码重置的邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:16:22 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3<br>偏重的研究方向：Meta;epidemiology;Cancer<br>经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077723, encodeId=879010e772339, content=挺好的，审稿接收快。之前中过一篇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/15/f7f2b6fa740df678d917e5f3794e5f11.jpg, createdBy=3b832056782, createdName=lambofgod, createdTime=Tue Dec 07 12:57:30 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954201, encodeId=cb2f954201de, content=Under Evaluation已然2周了，催稿没有回复请问这个状态是否正常？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLlINtMomu7O8KxsBW5vjfZau6S8ibwBPphK72hkHBb60gAlxB81LJib2lmRibVUmoBkg0Zry8ZWGPicA/132, createdBy=421e2171722, createdName=走散的晴天, createdTime=Tue Apr 06 13:57:17 CST 2021, time=2021-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120726, encodeId=18a62120e268e, content=请问一般under evaluation几天呀，已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90f98527616, createdName=ms3000001615675881, createdTime=Tue Mar 21 10:52:33 CST 2023, time=2023-03-21, status=1, ipAttribution=弗吉尼亚), GetPortalCommentsPageByObjectIdResponse(id=2115287, encodeId=3d99211528e03, content=偏重的研究方向：Cancer<br>经验分享：请问这个杂志接收生信和试验结合的临床文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70e15211770, createdName=1475fbf4m67暂无昵称, createdTime=Sat Feb 18 18:24:57 CST 2023, time=2023-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1238658, encodeId=36641238658e8, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享：Under evaluation<br><br>IJC-22-1946<br>好几天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小郝, createdTime=Sun Aug 14 17:48:05 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193008, encodeId=1bad11930087c, content=请问这个杂志要求提供原始数据吗？细胞STR鉴定是必须的吗？如果是那什么时候会要呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3b5453190, createdName=ms5000001945010335, createdTime=Sun Feb 13 17:05:02 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880588, encodeId=4269880588d1, content=请问这个杂志收综述嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201025/8eb3ba664d3e470b851a46cc65b07783/2838e99db9824e3ab062239a32b94ea0.jpg, createdBy=e8705227503, createdName=14792e5am71(暂无昵称), createdTime=Sat Aug 29 13:51:28 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079809, encodeId=980410e980994, content=想问下各位大佬，为什么我收不到密码重置的邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:27:38 CST 2021, time=2021-12-14, status=1, ipAttribution=)]
    2023-02-18 1475fbf4m67暂无昵称 来自上海

    偏重的研究方向：Cancer
    经验分享：请问这个杂志接收生信和试验结合的临床文章嘛

    1

    展开1条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=1079807, encodeId=415e10e98073a, content=想问下各位大佬，为什么我收不到密码重置的邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:16:22 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3<br>偏重的研究方向：Meta;epidemiology;Cancer<br>经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077723, encodeId=879010e772339, content=挺好的，审稿接收快。之前中过一篇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/15/f7f2b6fa740df678d917e5f3794e5f11.jpg, createdBy=3b832056782, createdName=lambofgod, createdTime=Tue Dec 07 12:57:30 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954201, encodeId=cb2f954201de, content=Under Evaluation已然2周了，催稿没有回复请问这个状态是否正常？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLlINtMomu7O8KxsBW5vjfZau6S8ibwBPphK72hkHBb60gAlxB81LJib2lmRibVUmoBkg0Zry8ZWGPicA/132, createdBy=421e2171722, createdName=走散的晴天, createdTime=Tue Apr 06 13:57:17 CST 2021, time=2021-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120726, encodeId=18a62120e268e, content=请问一般under evaluation几天呀，已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90f98527616, createdName=ms3000001615675881, createdTime=Tue Mar 21 10:52:33 CST 2023, time=2023-03-21, status=1, ipAttribution=弗吉尼亚), GetPortalCommentsPageByObjectIdResponse(id=2115287, encodeId=3d99211528e03, content=偏重的研究方向：Cancer<br>经验分享：请问这个杂志接收生信和试验结合的临床文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70e15211770, createdName=1475fbf4m67暂无昵称, createdTime=Sat Feb 18 18:24:57 CST 2023, time=2023-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1238658, encodeId=36641238658e8, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享：Under evaluation<br><br>IJC-22-1946<br>好几天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小郝, createdTime=Sun Aug 14 17:48:05 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193008, encodeId=1bad11930087c, content=请问这个杂志要求提供原始数据吗？细胞STR鉴定是必须的吗？如果是那什么时候会要呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3b5453190, createdName=ms5000001945010335, createdTime=Sun Feb 13 17:05:02 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880588, encodeId=4269880588d1, content=请问这个杂志收综述嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201025/8eb3ba664d3e470b851a46cc65b07783/2838e99db9824e3ab062239a32b94ea0.jpg, createdBy=e8705227503, createdName=14792e5am71(暂无昵称), createdTime=Sat Aug 29 13:51:28 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079809, encodeId=980410e980994, content=想问下各位大佬，为什么我收不到密码重置的邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:27:38 CST 2021, time=2021-12-14, status=1, ipAttribution=)]
    2022-08-14 庸医小郝

    审稿速度:1.0 | 投稿命中率:95.0
    经验分享：Under evaluation

    IJC-22-1946
    好几天了

    1

    展开1条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=1079807, encodeId=415e10e98073a, content=想问下各位大佬，为什么我收不到密码重置的邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:16:22 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3<br>偏重的研究方向：Meta;epidemiology;Cancer<br>经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077723, encodeId=879010e772339, content=挺好的，审稿接收快。之前中过一篇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/15/f7f2b6fa740df678d917e5f3794e5f11.jpg, createdBy=3b832056782, createdName=lambofgod, createdTime=Tue Dec 07 12:57:30 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954201, encodeId=cb2f954201de, content=Under Evaluation已然2周了，催稿没有回复请问这个状态是否正常？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLlINtMomu7O8KxsBW5vjfZau6S8ibwBPphK72hkHBb60gAlxB81LJib2lmRibVUmoBkg0Zry8ZWGPicA/132, createdBy=421e2171722, createdName=走散的晴天, createdTime=Tue Apr 06 13:57:17 CST 2021, time=2021-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120726, encodeId=18a62120e268e, content=请问一般under evaluation几天呀，已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90f98527616, createdName=ms3000001615675881, createdTime=Tue Mar 21 10:52:33 CST 2023, time=2023-03-21, status=1, ipAttribution=弗吉尼亚), GetPortalCommentsPageByObjectIdResponse(id=2115287, encodeId=3d99211528e03, content=偏重的研究方向：Cancer<br>经验分享：请问这个杂志接收生信和试验结合的临床文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70e15211770, createdName=1475fbf4m67暂无昵称, createdTime=Sat Feb 18 18:24:57 CST 2023, time=2023-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1238658, encodeId=36641238658e8, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享：Under evaluation<br><br>IJC-22-1946<br>好几天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小郝, createdTime=Sun Aug 14 17:48:05 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193008, encodeId=1bad11930087c, content=请问这个杂志要求提供原始数据吗？细胞STR鉴定是必须的吗？如果是那什么时候会要呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3b5453190, createdName=ms5000001945010335, createdTime=Sun Feb 13 17:05:02 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880588, encodeId=4269880588d1, content=请问这个杂志收综述嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201025/8eb3ba664d3e470b851a46cc65b07783/2838e99db9824e3ab062239a32b94ea0.jpg, createdBy=e8705227503, createdName=14792e5am71(暂无昵称), createdTime=Sat Aug 29 13:51:28 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079809, encodeId=980410e980994, content=想问下各位大佬，为什么我收不到密码重置的邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:27:38 CST 2021, time=2021-12-14, status=1, ipAttribution=)]
    2022-02-13 ms5000001945010335

    请问这个杂志要求提供原始数据吗？细胞STR鉴定是必须的吗？如果是那什么时候会要呢

    1

    展开1条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=1079807, encodeId=415e10e98073a, content=想问下各位大佬，为什么我收不到密码重置的邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:16:22 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3<br>偏重的研究方向：Meta;epidemiology;Cancer<br>经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077723, encodeId=879010e772339, content=挺好的，审稿接收快。之前中过一篇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/15/f7f2b6fa740df678d917e5f3794e5f11.jpg, createdBy=3b832056782, createdName=lambofgod, createdTime=Tue Dec 07 12:57:30 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954201, encodeId=cb2f954201de, content=Under Evaluation已然2周了，催稿没有回复请问这个状态是否正常？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLlINtMomu7O8KxsBW5vjfZau6S8ibwBPphK72hkHBb60gAlxB81LJib2lmRibVUmoBkg0Zry8ZWGPicA/132, createdBy=421e2171722, createdName=走散的晴天, createdTime=Tue Apr 06 13:57:17 CST 2021, time=2021-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120726, encodeId=18a62120e268e, content=请问一般under evaluation几天呀，已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90f98527616, createdName=ms3000001615675881, createdTime=Tue Mar 21 10:52:33 CST 2023, time=2023-03-21, status=1, ipAttribution=弗吉尼亚), GetPortalCommentsPageByObjectIdResponse(id=2115287, encodeId=3d99211528e03, content=偏重的研究方向：Cancer<br>经验分享：请问这个杂志接收生信和试验结合的临床文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70e15211770, createdName=1475fbf4m67暂无昵称, createdTime=Sat Feb 18 18:24:57 CST 2023, time=2023-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1238658, encodeId=36641238658e8, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享：Under evaluation<br><br>IJC-22-1946<br>好几天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小郝, createdTime=Sun Aug 14 17:48:05 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193008, encodeId=1bad11930087c, content=请问这个杂志要求提供原始数据吗？细胞STR鉴定是必须的吗？如果是那什么时候会要呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3b5453190, createdName=ms5000001945010335, createdTime=Sun Feb 13 17:05:02 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880588, encodeId=4269880588d1, content=请问这个杂志收综述嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201025/8eb3ba664d3e470b851a46cc65b07783/2838e99db9824e3ab062239a32b94ea0.jpg, createdBy=e8705227503, createdName=14792e5am71(暂无昵称), createdTime=Sat Aug 29 13:51:28 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079809, encodeId=980410e980994, content=想问下各位大佬，为什么我收不到密码重置的邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:27:38 CST 2021, time=2021-12-14, status=1, ipAttribution=)]
    2020-08-29 14792e5am71(暂无昵称)

    请问这个杂志收综述嘛

    1

    展开1条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=1079807, encodeId=415e10e98073a, content=想问下各位大佬，为什么我收不到密码重置的邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:16:22 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3<br>偏重的研究方向：Meta;epidemiology;Cancer<br>经验分享：International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审，只有一个审稿人审稿，审稿意见比较少，没有实质性的修改意见，这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出，或者工作量不是特别的大，建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077723, encodeId=879010e772339, content=挺好的，审稿接收快。之前中过一篇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/15/f7f2b6fa740df678d917e5f3794e5f11.jpg, createdBy=3b832056782, createdName=lambofgod, createdTime=Tue Dec 07 12:57:30 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954201, encodeId=cb2f954201de, content=Under Evaluation已然2周了，催稿没有回复请问这个状态是否正常？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLlINtMomu7O8KxsBW5vjfZau6S8ibwBPphK72hkHBb60gAlxB81LJib2lmRibVUmoBkg0Zry8ZWGPicA/132, createdBy=421e2171722, createdName=走散的晴天, createdTime=Tue Apr 06 13:57:17 CST 2021, time=2021-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120726, encodeId=18a62120e268e, content=请问一般under evaluation几天呀，已经10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90f98527616, createdName=ms3000001615675881, createdTime=Tue Mar 21 10:52:33 CST 2023, time=2023-03-21, status=1, ipAttribution=弗吉尼亚), GetPortalCommentsPageByObjectIdResponse(id=2115287, encodeId=3d99211528e03, content=偏重的研究方向：Cancer<br>经验分享：请问这个杂志接收生信和试验结合的临床文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70e15211770, createdName=1475fbf4m67暂无昵称, createdTime=Sat Feb 18 18:24:57 CST 2023, time=2023-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1238658, encodeId=36641238658e8, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享：Under evaluation<br><br>IJC-22-1946<br>好几天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小郝, createdTime=Sun Aug 14 17:48:05 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193008, encodeId=1bad11930087c, content=请问这个杂志要求提供原始数据吗？细胞STR鉴定是必须的吗？如果是那什么时候会要呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3b5453190, createdName=ms5000001945010335, createdTime=Sun Feb 13 17:05:02 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880588, encodeId=4269880588d1, content=请问这个杂志收综述嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201025/8eb3ba664d3e470b851a46cc65b07783/2838e99db9824e3ab062239a32b94ea0.jpg, createdBy=e8705227503, createdName=14792e5am71(暂无昵称), createdTime=Sat Aug 29 13:51:28 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079809, encodeId=980410e980994, content=想问下各位大佬，为什么我收不到密码重置的邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:27:38 CST 2021, time=2021-12-14, status=1, ipAttribution=)]
    2021-12-14 ms9482609815413700

    想问下各位大佬，为什么我收不到密码重置的邮件呢

    1

    展开1条回复
共500条页码: 4/50页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分